Mresvia (Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In)

The product contains a single‑stranded, 5'‑capped mRNA that encodes the RSV F glycoprotein. After injection, host cells translate the mRNA into the F protein, which is recognized by the immune system, prompting the production of neutralising antibodies and cellular immunity that protect against future RSV exposure.

The dose and schedule of Mresvia are determined by the prescribing healthcare professional based on the patient’s age, health status, and local immunisation guidelines. No fixed regimen is provided here; the prescriber sets the appropriate regimen.

Safety data for Mresvia in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Mresvia product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Mresvia uses an mRNA platform that delivers the RSV F glycoprotein directly to host cells, whereas many other RSV vaccines rely on recombinant protein or live‑attenuated virus approaches. The mRNA technology can induce both humoral and cellular immunity and may offer manufacturing advantages, but comparative efficacy and safety depend on clinical trial data for each product.

Mresvia must be stored refrigerated at 2‑8 °C. Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking. Follow cold‑chain procedures during transport to maintain product integrity.

Mresvia is given as an intramuscular injection, typically into the deltoid muscle of the upper arm. The injection should be performed by a qualified healthcare professional using aseptic technique and the appropriate needle size for the patient’s age and body weight.

Serious adverse events, although rare, can include anaphylaxis, Guillain‑Barré syndrome, myocarditis, thrombocytopenia, and severe neurological reactions. Patients should be observed after vaccination and seek immediate medical attention if they experience signs of a severe allergic reaction or neurological symptoms.

Mresvia is contraindicated in individuals with a known severe allergy to any component of the vaccine. It should also be used with caution in pregnant or breastfeeding women, and in patients receiving high‑dose immunosuppressive therapy, where the immune response may be diminished.